However, the mutually exclusive relation observed between mutations in TP53 and EGFR in gliomas suggests that other mechanisms, different from GOF activities of mutant p53 proteins, could be responsible for the regulation of EGFR turnover in the most aggressive tumors, those that accumulate alterations in the receptor’s gene. The gene discussed is EGFR; the disease is central nervous system cancer.